Environmental exposure unit: A sensitive, specific, and reproducible methodology for allergen challenge

Annals of Allergy, Asthma and Immunology

Volumn 111, Issue 5, 2013, Pages 323-328

  Ellis, Anne K ^a,b   North, Michelle L ^a   Walker, Terry ^b   Steacy, Lisa M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FEXOFENADINE; IMMUNOMODULATING AGENT; LEUKOTRIENE DERIVATIVE; LEVOCETIRIZINE; LORATADINE; LORATADINE PLUS MONTELUKAST; MONTELUKAST; PHENYLEPHRINE; PLACEBO; TERFENADINE; UNCLASSIFIED DRUG;

ADAPTATION; ALLERGENICITY; ALLERGIC RHINITIS; ANAPHYLAXIS; CLINICAL FEATURE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; EDUCATION; ENVIRONMENTAL EXPOSURE; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; PATIENT SAFETY; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; RHINOCONJUNCTIVITIS; SOCIOECONOMICS; SYMPTOMATOLOGY; TERTIARY HEALTH CARE;

ALLERGENS; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIAL PROVOCATION TESTS; BRONCHODILATOR AGENTS; ENVIRONMENTAL EXPOSURE; HUMANS; PREGNADIENEDIOLS; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84886880280     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2013.07.019     Document Type: Review

References (58)

1. J. Bousquet, P. Van Cauwenberge, and N. Khaltaev Allergic rhinitis and its impact on asthma J Allergy Clin Immunol 108 2001 S147 S334
2. E.O. Meltzer, M.S. Blaiss, and M.J. Derebery Burden of allergic rhinitis: results from the Pediatric Allergies in America survey J Allergy Clin Immunol 124 2009 S43 S70
3. E.O. Meltzer, G.N. Gross, R. Katial, and W.W. Storms Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations J Fam Pract 61 2012 S5 S10
4. J.H. Day, M.P. Briscoe, and G.W. Canonica The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper Clin Exp Allergy Rev 6 2006 31 59
5. H.F. Pross, J.H. Day, R.H. Clark, and R.E. Lees Immunologic studies of subjects with asthma exposed to formaldehyde and urea-formaldehyde foam insulation (UFFI) off products J Allergy Clin Immunol 79 1987 797 810
6. J.H. Day, R.E. Lees, R.H. Clark, and P.L. Pattee Respiratory response to formaldehyde and off-gas of urea formaldehyde foam insulation Can Med Assoc J 131 1984 1061 1065
7. Environmental Exposure Unit. What is the EEU? Available at: www.eeu.on.ca. Accessed April 30, 2013.
8. E.O. Meltzer, R.B. Berkowitz, and E.B. Grossbard An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment J Allergy Clin Immunol 115 2005 791 796
9. E.O. Meltzer, T.B. Casale, and M.S. Gold Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study Ann Allergy Asthma Immunol 90 2003 79 86
10. H.J. Davies Exposure of hay fever subjects to an indoor environmental grass pollen challenge system Clin Allergy 15 1985 419 427
11. F. Horak, and S. Jäger The Vienna challenge chamber (VCC) - a new method for allergen exposition tests Wien Klin Wocheschr 99 1987 509 510
12. S.M. Rønborg, H. Mosbech, C.R. Johnsen, and L.K. Poulsen Exposure chamber for allergen challenge. The development and validation of a new concept Allergy 51 1996 82 88
13. R.B. Berkowitz, G.G. Woodworth, and C. Lutz Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit Ann Allergy Asthma Immunol 89 2002 38 45
14. J.A. Wilken, R. Berkowitz, and R. Kane Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis Ann Allergy Asthma Immunol 89 2002 372 380
15. R.B. Berkowitz, F. McCafferty, and C. Lutz Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies Clin Ther 28 2006 1658 1669
16. P. Patel, C. D'Andrea, and H.J. Sacks Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber Am J Rhinol 21 2007 499 503
17. P. Patel, and A.M. Salapatek Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine Expert Rev Vaccines 5 2006 617 629
18. D.A. Ramirez, R.L. Jacobs, and C.P. Andrews Uniperus asheii (mountain cedar) pollen utilized as an antigen in the biogenics chamber: comparison of natural and controlled exposures J Allergy Clin Immunol 127 2011 AB19
19. R.L. Jacobs, D.A. Ramirez, and C.P. Andrews Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen Ann Allergy Asthma Immunol 107 2011 133 138
20. Crampton HJ, Gomez P. A pilot study evaluating the signs and symptoms of seasonal allergic rhinitis and conjunctivitis following allergen exposure in the Allergen BioCube. Available at: http://www.clinicaltrials.gov/ct2/show/ NCT00985075?term=allergen+biocube&rank=1. Accessed August 8, 2013.
21. V.A. Varney, J. Edwards, K. Tabbah, H. Brewster, G. Mavroleon, and A.J. Frew Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial Clin Exp Allergy 27 1997 860 867
22. R.A. Wood, and P.A. Eggleston The effects of intranasal steroids on nasal and pulmonary responses to cat exposure Am J Respir Crit Care Med 151 1995 315 320
23. P.S. Norman, J.L. Ohman Jr., and A.A. Long Treatment of cat allergy with T-cell reactive peptides Am J Respir Crit Care Med 154 1996 1623 1628
24. J.H. Day, and M.P. Briscoe Environmental exposure unit: a system to test anti-allergic treatment Ann Allergy Asthma Immunol 83 1999 83 89 quiz 89-93
25. J.H. Day, M.P. Briscoe, E. Rafeiro, A.K. Ellis, E. Pettersson, and A. Akerlund Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model J Allergy Clin Immunol 105 2000 489 494
26. A.K. Ellis, L.M. Steacy, and T. Walker Clinical validation of controlled grass pollen challenge in the Environmental Exposure Unit (EEU) J Allergy Clin Immunol 129 2012 AB112
27. J.H. Day, A.K. Ellis, E. Rafeiro, J.D. Ratz, and M.P. Briscoe Experimental models for the evaluation of treatment of allergic rhinitis Ann Allergy Asthma Immunol 96 2006 263 277 quiz 277-278, 315
28. J.H. Day, M.P. Briscoe, E. Rafeiro, C. Schrewelius, B. Simpson, and L. O'Dowd A comparison of rofleponide palmitate nasal spray (RPNS) with budesonide aqueous nasal spray (BANS) and placebo for seasonal allergic rhinitis (AR) using the Environmental Expsoure Unit (EEU) J Allergy Clin Immunol 113 suppl 2 2004 S202
29. J.T. Connell Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis J Allergy 43 1969 33 44
30. A.K. Ellis, J.D. Ratz, A.G. Day, and J.H. Day Factors that affect the allergic rhinitis response to ragweed allergen exposure Ann Allergy Asthma Immunol 104 2010 293 298
31. A.K. Ellis, and J.H. Day Diagnosis and management of anaphylaxis CMAJ 169 2003 307 311
32. A.K. Ellis, and J.H. Day The role of epinephrine in the treatment of anaphylaxis Curr Allergy Asthma Rep 3 2003 11 14
33. F.E. Simons, L.R. Ardusso, and M.B. Bilo Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis Curr Opin Allergy Clin Immunol 12 2012 389 399
34. A.K. Ellis, J.H. Day, and M.J. Lundie Impact on quality of life during an allergen challenge research trial Ann Allergy Asthma Immunol 83 1999 33 39
35. A.K. Ellis, E. Rafeiro, and J.H. Day Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis Ann Allergy Asthma Immunol 86 2001 393 396
36. F. Horak, U.P. Stubner, R. Zieglmayer, and A.G. Harris Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit J Allergy Clin Immunol 109 2002 956 961
37. F. Horak, P. Stubner, R. Zieglmeyer, and A.G. Harris Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure Allergy 58 2003 481 485
38. J.H. Day, M. Briscoe, E. Rafeiro, D. Chapman, and B. Kramer Comparative onset of action and symptom relief with cetirizine, loratadine, or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system Ann Allergy Asthma Immunol 87 2001 474 481
39. J.H. Day, M. Briscoe, and M.D. Widlitz Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit J Allergy Clin Immunol 101 1998 638 645
40. R.L. Jacobs, N. Harper, and W. He Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes J Allergy Clin Immunol 130 2012 122 127
41. Food and Drug Administration Draft Guidance for Industry - Allergic Rhinitis: Clinical Development Programs for Drug Products 2000 US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research Washington, DC
42. European Medicines Agency (EMA) and Committee for Medicinal Products for Human Use (CHMP). Guideline on the Clinical Development of Medicinal Products for the Treatment of Allergic Rhinoconjunctivitis. London, UK: European Medicines Agency; 2005.
43. R.K. Katial, A.M. Salapatek, and P. Patel Establishing the onset of action of intranasal corticosteroids: is there an ideal study design? Allergy Asthma Proc 30 2009 595 604
44. J.T. Connell A novel method to assess antihistamine and decongestant efficacy Ann Allergy 42 1979 278 285
45. G. D'Amato Urban air pollution and plant-derived respiratory allergy Clin Exp Allergy 30 2000 628 636
46. J.H. Day, M.P. Briscoe, R.H. Clark, A.K. Ellis, and P. Gervais Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis Ann Allergy Asthma Immunol 79 1997 163 172
47. J.H. Day, M.P. Briscoe, and A. Welsh Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit Ann Allergy Asthma Immunol 79 1997 533 540
48. J.H. Day, M.P. Briscoe, and E. Rafeiro Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit Allergy Asthma Proc 26 2005 275 282
49. J.H. Day, M.P. Briscoe, E. Rafeiro, D. Hewlett Jr., D. Chapman, and B. Kramer Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis Allergy Asthma Proc 25 2004 59 68
50. J.H. Day, M.P. Briscoe, and J.D. Ratz Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit Allergy Asthma Proc 29 2008 304 312
51. J.H. Day, M.P. Briscoe, and J.D. Ratz Efficacy of levocetirizine, an antihistamine, compared with montelukast, a leukotriene receptor antagonist, in subjects with seasonal allergic rhinitis in the Environmental Exposure Unit Allergy Asthma Clin Immunol 4 suppl 1 2008 28
52. J.H. Day, M.P. Briscoe, J.D. Ratz, M. Danzig, and R. Yao Efficacy of loratadine/montelukast combination and phenylephrine on nasal congestion in subjects with seasonal allergic rhinitis in the environmental exposure unit Allergy Asthma Clin Immunol 4 supple 1 2008 29
53. J.H. Day, M.P. Briscoe, J.D. Ratz, A.K. Ellis, R. Yao, and M. Danzig Onset of action of loratadine/montelukast in seasonal allergic rhinitis subjects exposed to ragweed pollen in the Environmental Exposure Unit Allergy Asthma Proc 30 2009 270 276
54. A.K. Ellis, Y. Zhu, L.M. Steacy, T. Walker, and J.H. Day A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis Allergy Asthma Clin Immunol 2013;9:16
55. J.H. Day, K. Nolop, and B.N. Lutsky 194-079 Study Group. Comparison of once-daily treatment with mometasone furonate (Nasonex TM) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis J Allergy Clin Immunol 99 1997 S441
56. J.H. Day, D.L. Buckeridge, R.H. Clark, M.P. Briscoe, and R. Phillips A randomized, double-blind, placebo-controlled, controlled antigen delivery study of the onset of action of aerosolized triamcinolone acetonide nasal spray in subjects with ragweed-induced allergic rhinitis J Allergy Clin Immunol 97 1996 1050 1057
57. J.P. Donovan, D.L. Buckeridge, M.P. Briscoe, R.H. Clark, and J.H. Day Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure Ann Allergy Asthma Immunol 77 1996 74 80
58. F. Horak, P. Zieglmayer, and R. Zieglmayer Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber J Allergy Clin Immunol 124 2009 471 477.e1